Pfizer Inc. (PFE) announced Tuesday that its Braftovi cancer treatment regimen delivered strong results in a pivotal trial for metastatic colorectal cancer, showing statistically significant improvement in how long patients lived without their disease progressing.

The results come from a specific subset of patients whose tumors carry a particular genetic mutation, which represents a meaningful advance for this patient population that has historically faced challenging treatment outcomes.

What the Trial Data Shows

Pfizer released topline progression-free survival results from Cohort 3 of its BREAKWATER trial, which evaluated Braftovi (encorafenib) combined with cetuximab (marketed as Erbitux) and Folfiri (a chemotherapy cocktail of fluorouracil, leucovorin, and irinotecan) in previously untreated patients with metastatic colorectal cancer harboring a BRAF V600E mutation.

This follows earlier data from the same trial that already showed promising signs. Back in January, Pfizer shared results demonstrating that the Braftovi combination regimen achieved a clinically meaningful and statistically significant improvement in confirmed objective response rate compared to standard treatment. Specifically, 64.4% of patients on the Braftovi regimen saw their tumors respond versus 39.2% on standard-of-care FOLFIRI with or without bevacizumab. That translates to an odds ratio of 2.76 with a p-value of 0.001, which in plain English means the difference is real and unlikely due to chance.

Looking at the overall Phase 3 BREAKWATER trial, the results showed a clinically meaningful and statistically significant improvement in confirmed objective response rate compared to patients receiving chemotherapy with or without bevacizumab, with response rates of 60.9% versus 40.0%.

What the Stock Is Doing

Currently, Pfizer shares are trading 3.5% below the 20-day simple moving average and 5.2% below the 100-day simple moving average, suggesting some near-term softness. Over the past year, shares have climbed 7.90% and are positioned closer to their 52-week highs than lows.

The technical picture shows mixed signals. The RSI sits at 44.45, which is neutral territory indicating the stock is neither overbought nor oversold. Meanwhile, the MACD indicator is below its signal line, pointing to bearish pressure. Together, these suggest the stock is in a bit of a holding pattern momentum-wise.

• Key Resistance: $27.50
• Key Support: $24.50

What Analysts Are Saying

The stock carries a Hold rating with an average price target of $29.67 among analysts. Recent analyst actions include:

• Cantor Fitzgerald: Neutral rating (maintains $27 price target)
• Cantor Fitzgerald: Neutral rating (raises target to $27)
• UBS: Neutral rating ($25 price target)

ETF Exposure

For investors who prefer ETF exposure to Pfizer, here are the top funds with significant weightings:

• First Trust Morningstar Dividend Leaders Index Fund (FDL): 5.87% weight
• Invesco Pharmaceuticals ETF (PJP): 5.01% weight
• Franklin US Dividend Booster Index ETF (XUDV): 4.90% weight

Price Action: Pfizer shares were up 0.63% at $27.75 at the time of publication Tuesday, trading near the 52-week high of $27.94.